#FORMAT=WebAnno TSV 3.3
#T_SP=webanno.custom.ConceptLayer|identifier


1-1	0-10	Expression	_
1-2	11-13	of	_
1-3	14-22	dopamine	_
1-4	23-25	D2	_
1-5	26-29	and	_
1-6	30-32	D3	_
1-7	33-42	receptors	_
1-8	43-45	in	_
1-9	46-49	the	_
1-10	50-55	human	_
1-11	56-62	retina	_
1-12	63-71	revealed	_
1-13	72-74	by	_
1-14	75-83	positron	_
1-15	84-92	emission	_
1-16	93-103	tomography	_
1-17	104-107	and	_
1-18	108-116	targeted	_
1-19	117-121	mass	_
1-20	122-134	spectrometry	_
1-21	135-143	Dopamine	_
1-22	144-146	D2	_
1-23	147-156	receptors	_
1-24	157-158	(	_
1-25	159-162	D2R	_
1-26	163-164	)	_
1-27	165-168	are	_
1-28	169-178	expressed	_
1-29	179-181	in	_
1-30	182-185	the	_
1-31	186-191	human	_
1-32	192-198	retina	_
1-33	199-202	and	_
1-34	203-207	play	_
1-35	208-210	an	_
1-36	211-220	important	_
1-37	221-225	role	_
1-38	226-228	in	_
1-39	229-232	the	_
1-40	233-243	modulation	_
1-41	244-246	of	_
1-42	247-253	neural	_
1-43	254-263	responses	_
1-44	264-266	to	_
1-45	267-283	light-adaptation	_
1-46	284-285	.	_

2-1	286-293	However	_
2-2	294-295	,	_
2-3	296-298	it	_
2-4	299-301	is	_
2-5	302-309	unknown	_
2-6	310-317	whether	_
2-7	318-326	dopamine	_
2-8	327-329	D3	_
2-9	330-339	receptors	_
2-10	340-341	(	_
2-11	342-345	D3R	_
2-12	346-347	)	_
2-13	348-351	are	_
2-14	352-361	expressed	_
2-15	362-364	in	_
2-16	365-368	the	_
2-17	369-374	human	_
2-18	375-381	retina	_
2-19	382-383	.	_

3-1	384-389	Using	_
3-2	390-398	positron	http://maven.renci.org/NeuroBridge/neurobridge#PositronEmissionTomography
3-3	399-407	emission	_
3-4	408-418	tomography	http://maven.renci.org/NeuroBridge/neurobridge#PositronEmissionTomography
3-5	419-420	(	_
3-6	421-424	PET	_
3-7	425-426	)	_
3-8	427-428	,	_
3-9	429-431	we	_
3-10	432-436	have	_
3-11	437-445	observed	_
3-12	446-457	significant	_
3-13	458-464	uptake	_
3-14	465-467	of	_
3-15	468-471	the	_
3-16	472-486	D3R-preferring	_
3-17	487-494	agonist	_
3-18	495-506	radiotracer	_
3-19	507-508	[	_
3-20	509-512	11C	_
3-21	513-514	]	_
3-22	515-516	-	_
3-23	517-518	(	_
3-24	519-520	+	_
3-25	521-522	)	_
3-26	523-528	-PHNO	_
3-27	529-533	into	_
3-28	534-537	the	_
3-29	538-544	retina	_
3-30	545-547	of	_
3-31	548-554	humans	_
3-32	555-557	in	_
3-33	558-562	vivo	_
3-34	563-564	.	_

4-1	565-569	This	_
4-2	570-573	led	_
4-3	574-576	us	_
4-4	577-579	to	_
4-5	580-587	examine	_
4-6	588-595	whether	_
4-7	596-597	[	_
4-8	598-601	11C	_
4-9	602-603	]	_
4-10	604-605	-	_
4-11	606-607	(	_
4-12	608-609	+	_
4-13	610-611	)	_
4-14	612-617	-PHNO	_
4-15	618-625	binding	_
4-16	626-628	in	_
4-17	629-632	the	_
4-18	633-639	retina	_
4-19	640-643	was	_
4-20	644-656	quantifiable	_
4-21	657-662	using	_
4-22	663-672	reference	_
4-23	673-679	tissue	_
4-24	680-687	methods	_
4-25	688-691	and	_
4-26	692-694	if	_
4-27	695-698	D3R	_
4-28	699-702	are	_
4-29	703-712	expressed	_
4-30	713-715	in	_
4-31	716-721	human	_
4-32	722-733	post-mortem	_
4-33	734-741	retinal	_
4-34	742-748	tissue	_
4-35	749-750	.	_

5-1	751-752	[	_
5-2	753-756	11C	_
5-3	757-758	]	_
5-4	759-760	-	_
5-5	761-762	(	_
5-6	763-764	+	_
5-7	765-766	)	_
5-8	767-772	-PHNO	_
5-9	773-777	data	_
5-10	778-782	from	_
5-11	783-785	49	_
5-12	786-793	healthy	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder
5-13	794-802	controls	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder
5-14	803-804	(	_
5-15	805-809	mean	_
5-16	810-813	age	_
5-17	814-815	:	_
5-18	816-821	39.96	_
5-19	822-823	±	_
5-20	824-829	14.36	_
5-21	830-831	;	_
5-22	832-834	16	_
5-23	835-841	female	_
5-24	842-843	)	_
5-25	844-847	and	_
5-26	848-850	12	_
5-27	851-870	antipsychotic-naïve	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
5-28	871-879	patients	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
5-29	880-884	with	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
5-30	885-898	schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
5-31	899-900	(	_
5-32	901-905	mean	_
5-33	906-909	age	_
5-34	910-911	:	_
5-35	912-917	25.75	_
5-36	918-919	±	_
5-37	920-924	6.25	_
5-38	925-926	;	_
5-39	927-928	4	_
5-40	929-935	female	_
5-41	936-937	)	_
5-42	938-942	were	_
5-43	943-951	analyzed	_
5-44	952-953	.	_

6-1	954-956	We	_
6-2	957-965	observed	_
6-3	966-968	no	_
6-4	969-980	differences	_
6-5	981-983	in	_
6-6	984-985	[	_
6-7	986-989	11C	_
6-8	990-991	]	_
6-9	992-993	-	_
6-10	994-995	(	_
6-11	996-997	+	_
6-12	998-999	)	_
6-13	1000-1005	-PHNO	_
6-14	1006-1013	binding	_
6-15	1014-1016	in	_
6-16	1017-1020	the	_
6-17	1021-1027	retina	_
6-18	1028-1035	between	_
6-19	1036-1049	first-episode	http://maven.renci.org/NeuroBridge/neurobridge#FirstEpisodePsychosis
6-20	1050-1051	,	_
6-21	1052-1062	drug-naïve	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
6-22	1063-1071	patients	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
6-23	1072-1076	with	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
6-24	1077-1090	schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
6-25	1091-1094	and	_
6-26	1095-1102	healthy	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder
6-27	1103-1111	controls	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder
6-28	1112-1113	.	_

7-1	1114-1125	Post-mortem	_
7-2	1126-1133	retinal	_
7-3	1134-1141	tissues	_
7-4	1142-1146	from	_
7-5	1147-1151	four	_
7-6	1152-1159	healthy	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder
7-7	1160-1167	persons	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder
7-8	1168-1169	(	_
7-9	1170-1174	mean	_
7-10	1175-1178	age	_
7-11	1179-1180	:	_
7-12	1181-1186	59.75	_
7-13	1187-1188	±	_
7-14	1189-1193	9.11	_
7-15	1194-1195	;	_
7-16	1196-1197	2	_
7-17	1198-1204	female	_
7-18	1205-1206	)	_
7-19	1207-1210	and	_
7-20	1211-1215	four	_
7-21	1216-1224	patients	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
7-22	1225-1229	with	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
7-23	1230-1243	schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
7-24	1244-1245	(	_
7-25	1246-1250	mean	_
7-26	1251-1254	age	_
7-27	1255-1256	:	_
7-28	1257-1259	54	_
7-29	1260-1261	±	_
7-30	1262-1267	17.11	_
7-31	1268-1269	;	_
7-32	1270-1271	2	_
7-33	1272-1278	female	_
7-34	1279-1280	)	_
7-35	1281-1285	were	_
7-36	1286-1294	analyzed	_
7-37	1295-1300	using	_
7-38	1301-1302	a	_
7-39	1303-1311	targeted	_
7-40	1312-1316	mass	_
7-41	1317-1329	spectrometry	_
7-42	1330-1339	technique	_
7-43	1340-1341	:	_
7-44	1342-1350	parallel	_
7-45	1351-1359	reaction	_
7-46	1360-1370	monitoring	_
7-47	1371-1372	(	_
7-48	1373-1376	PRM	_
7-49	1377-1378	)	_
7-50	1379-1387	analysis	_
7-51	1388-1389	.	_

8-1	1390-1395	Using	_
8-2	1396-1404	targeted	_
8-3	1405-1409	mass	_
8-4	1410-1422	spectrometry	_
8-5	1423-1424	,	_
8-6	1425-1427	we	_
8-7	1428-1437	confirmed	_
8-8	1438-1442	that	_
8-9	1443-1446	D3R	_
8-10	1447-1450	are	_
8-11	1451-1460	expressed	_
8-12	1461-1463	in	_
8-13	1464-1469	human	_
8-14	1470-1477	retinal	_
8-15	1478-1484	tissue	_
8-16	1485-1487	ex	_
8-17	1488-1492	vivo	_
8-18	1493-1494	.	_

9-1	1495-1502	Notably	_
9-2	1503-1504	,	_
9-3	1505-1510	there	_
9-4	1511-1514	was	_
9-5	1515-1518	far	_
9-6	1519-1526	greater	_
9-7	1527-1537	expression	_
9-8	1538-1540	of	_
9-9	1541-1544	D2R	_
9-10	1545-1553	relative	_
9-11	1554-1556	to	_
9-12	1557-1560	D3R	_
9-13	1561-1563	in	_
9-14	1564-1567	the	_
9-15	1568-1575	healthy	_
9-16	1576-1581	human	_
9-17	1582-1588	retina	_
9-18	1589-1590	(	_
9-19	1591-1596	~12:1	_
9-20	1597-1598	)	_
9-21	1599-1600	.	_

10-1	1601-1609	Moreover	_
10-2	1610-1611	,	_
10-3	1612-1615	PRM	_
10-4	1616-1624	analysis	_
10-5	1625-1633	revealed	_
10-6	1634-1641	reduced	_
10-7	1642-1645	D2R	_
10-8	1646-1647	,	_
10-9	1648-1651	but	_
10-10	1652-1655	not	_
10-11	1656-1659	D3R	_
10-12	1660-1661	,	_
10-13	1662-1672	expression	_
10-14	1673-1675	in	_
10-15	1676-1679	the	_
10-16	1680-1687	retinas	_
10-17	1688-1690	of	_
10-18	1691-1700	non-first	http://maven.renci.org/NeuroBridge/neurobridge#FirstEpisodePsychosis
10-19	1701-1708	episode	_
10-20	1709-1717	patients	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
10-21	1718-1722	with	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
10-22	1723-1736	schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
10-23	1737-1745	compared	_
10-24	1746-1748	to	_
10-25	1749-1756	healthy	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder
10-26	1757-1765	controls	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder
10-27	1766-1767	.	_

11-1	1768-1770	We	_
11-2	1771-1778	confirm	_
11-3	1779-1783	that	_
11-4	1784-1787	D3R	_
11-5	1788-1791	are	_
11-6	1792-1801	expressed	_
11-7	1802-1804	in	_
11-8	1805-1808	the	_
11-9	1809-1814	human	_
11-10	1815-1821	retina	_
11-11	1822-1823	.	_

12-1	1824-1830	Future	_
12-2	1831-1838	studies	_
12-3	1839-1842	are	_
12-4	1843-1849	needed	_
12-5	1850-1852	to	_
12-6	1853-1862	determine	_
12-7	1863-1867	what	_
12-8	1868-1878	proportion	_
12-9	1879-1881	of	_
12-10	1882-1885	the	_
12-11	1886-1887	[	_
12-12	1888-1891	11C	_
12-13	1892-1893	]	_
12-14	1894-1895	-	_
12-15	1896-1897	(	_
12-16	1898-1899	+	_
12-17	1900-1901	)	_
12-18	1902-1907	-PHNO	_
12-19	1908-1914	signal	_
12-20	1915-1917	in	_
12-21	1918-1921	the	_
12-22	1922-1927	human	_
12-23	1928-1934	retina	_
12-24	1935-1937	in	_
12-25	1938-1942	vivo	_
12-26	1943-1945	is	_
12-27	1946-1949	due	_
12-28	1950-1952	to	_
12-29	1953-1960	binding	_
12-30	1961-1963	to	_
12-31	1964-1967	D3R	_
12-32	1968-1974	versus	_
12-33	1975-1978	D2R	_
12-34	1979-1980	.	_

13-1	1981-1990	Knowledge	_
13-2	1991-1995	that	_
13-3	1996-2000	both	_
13-4	2001-2004	D2R	_
13-5	2005-2008	and	_
13-6	2009-2012	D3R	_
13-7	2013-2016	are	_
13-8	2017-2026	expressed	_
13-9	2027-2029	in	_
13-10	2030-2033	the	_
13-11	2034-2039	human	_
13-12	2040-2046	retina	_
13-13	2047-2048	,	_
13-14	2049-2052	and	_
13-15	2053-2064	potentially	_
13-16	2065-2077	quantifiable	_
13-17	2078-2080	in	_
13-18	2081-2085	vivo	_
13-19	2086-2091	using	_
13-20	2092-2093	[	_
13-21	2094-2097	11C	_
13-22	2098-2099	]	_
13-23	2100-2101	-	_
13-24	2102-2103	(	_
13-25	2104-2105	+	_
13-26	2106-2107	)	_
13-27	2108-2113	-PHNO	_
13-28	2114-2115	,	_
13-29	2116-2121	poses	_
13-30	2122-2125	new	_
13-31	2126-2134	research	_
13-32	2135-2142	avenues	_
13-33	2143-2146	for	_
13-34	2147-2153	better	_
13-35	2154-2167	understanding	_
13-36	2168-2171	the	_
13-37	2172-2176	role	_
13-38	2177-2179	of	_
13-39	2180-2187	retinal	_
13-40	2188-2196	dopamine	_
13-41	2197-2199	in	_
13-42	2200-2205	human	_
13-43	2206-2212	vision	_
13-44	2213-2214	.	_

14-1	2215-2219	This	_
14-2	2220-2224	work	_
14-3	2225-2228	may	_
14-4	2229-2233	have	_
14-5	2234-2243	important	_
14-6	2244-2256	implications	_
14-7	2257-2260	for	_
14-8	2261-2272	elucidating	_
14-9	2273-2291	pathophysiological	_
14-10	2292-2295	and	_
14-11	2296-2309	antipsychotic	_
14-12	2310-2317	induced	_
14-13	2318-2324	visual	_
14-14	2325-2333	deficits	_
14-15	2334-2336	in	_
14-16	2337-2350	schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
14-17	2351-2352	.	_

15-1	2353-2354	2	_
15-2	2355-2356	.	_

16-1	2357-2365	Material	http://maven.renci.org/NeuroBridge/neurobridge#StudyMethod
16-2	2366-2369	and	http://maven.renci.org/NeuroBridge/neurobridge#StudyMethod
16-3	2370-2377	methods	http://maven.renci.org/NeuroBridge/neurobridge#StudyMethod
16-4	2378-2381	2.1	http://maven.renci.org/NeuroBridge/neurobridge#StudyMethod
16-5	2382-2383	.	http://maven.renci.org/NeuroBridge/neurobridge#StudyMethod

17-1	2384-2385	[	_
17-2	2386-2389	11C	_
17-3	2390-2391	]	_
17-4	2392-2393	-	_
17-5	2394-2395	(	_
17-6	2396-2397	+	_
17-7	2398-2399	)	_
17-8	2400-2405	-PHNO	_
17-9	2406-2418	participants	_
17-10	2419-2422	PET	http://maven.renci.org/NeuroBridge/neurobridge#PositronEmissionTomography
17-11	2423-2427	data	http://maven.renci.org/NeuroBridge/neurobridge#PositronEmissionTomography
17-12	2428-2432	from	_
17-13	2433-2440	healthy	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder
17-14	2441-2448	persons	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder
17-15	2449-2452	and	_
17-16	2453-2463	drug-naive	http://maven.renci.org/NeuroBridge/neurobridge#FirstEpisodePsychosis
17-17	2464-2471	persons	http://maven.renci.org/NeuroBridge/neurobridge#FirstEpisodePsychosis
17-18	2472-2476	with	http://maven.renci.org/NeuroBridge/neurobridge#FirstEpisodePsychosis
17-19	2477-2490	schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#FirstEpisodePsychosis
17-20	2491-2492	,	_
17-21	2493-2503	previously	_
17-22	2504-2512	reported	_
17-23	2513-2515	in	_
17-24	2516-2519	the	_
17-25	2520-2530	literature	_
17-26	2531-2532	,	_
17-27	2533-2537	were	_
17-28	2538-2549	re-analyzed	_
17-29	2550-2553	for	_
17-30	2554-2557	the	_
17-31	2558-2565	current	_
17-32	2566-2579	investigation	_
17-33	2580-2581	.	_

18-1	2582-2587	These	_
18-2	2588-2595	studies	_
18-3	2596-2600	were	_
18-4	2601-2609	approved	_
18-5	2610-2612	by	_
18-6	2613-2616	the	_
18-7	2617-2625	Research	_
18-8	2626-2632	Ethics	_
18-9	2633-2638	Board	_
18-10	2639-2641	of	_
18-11	2642-2645	the	_
18-12	2646-2652	Centre	_
18-13	2653-2656	for	_
18-14	2657-2666	Addiction	_
18-15	2667-2670	and	_
18-16	2671-2677	Mental	_
18-17	2678-2684	Health	_
18-18	2685-2686	(	_
18-19	2687-2691	CAMH	_
18-20	2692-2693	)	_
18-21	2694-2695	,	_
18-22	2696-2703	Toronto	_
18-23	2704-2705	.	_

19-1	2706-2713	Healthy	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder
19-2	2714-2726	participants	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder
19-3	2727-2731	were	_
19-4	2732-2744	right-handed	_
19-5	2745-2751	adults	_
19-6	2752-2756	free	_
19-7	2757-2759	of	_
19-8	2760-2763	any	_
19-9	2764-2769	major	_
19-10	2770-2777	medical	_
19-11	2778-2780	or	_
19-12	2781-2792	psychiatric	_
19-13	2793-2802	disorders	_
19-14	2803-2805	as	_
19-15	2806-2816	determined	_
19-16	2817-2819	by	_
19-17	2820-2828	clinical	_
19-18	2829-2838	interview	_
19-19	2839-2840	,	_
19-20	2841-2844	the	_
19-21	2845-2849	Mini	_
19-22	2850-2863	International	_
19-23	2864-2880	Neuropsychiatric	http://maven.renci.org/NeuroBridge/neurobridge#MentalHealthDiagnosisScale
19-24	2881-2895	Interview-Plus	http://maven.renci.org/NeuroBridge/neurobridge#MentalHealthDiagnosisScale
19-25	2896-2897	(	_
19-26	2898-2907	MINI-Plus	_
19-27	2908-2909	)	_
19-28	2910-2911	,	_
19-29	2912-2917	basic	_
19-30	2918-2926	clinical	_
19-31	2927-2937	laboratory	_
19-32	2938-2943	tests	_
19-33	2944-2945	,	_
19-34	2946-2949	and	_
19-35	2950-2969	electrocardiography	_
19-36	2970-2971	.	_

20-1	2972-2984	Participants	_
20-2	2985-2989	with	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
20-3	2990-3003	schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
20-4	3004-3008	were	_
20-5	3009-3028	antipsychotic-naïve	_
20-6	3029-3032	and	_
20-7	3033-3036	met	_
20-8	3037-3045	criteria	_
20-9	3046-3049	for	_
20-10	3050-3053	the	_
20-11	3054-3063	diagnosis	_
20-12	3064-3066	of	_
20-13	3067-3080	schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
20-14	3081-3083	or	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
20-15	3084-3099	schizoaffective	http://maven.renci.org/NeuroBridge/neurobridge#BipolarTypeSchizoaffectiveDisorder
20-16	3100-3108	disorder	http://maven.renci.org/NeuroBridge/neurobridge#BipolarTypeSchizoaffectiveDisorder
20-17	3109-3114	based	_
20-18	3115-3117	on	_
20-19	3118-3121	the	_
20-20	3122-3128	DSM-IV	_
20-21	3129-3132	and	_
20-22	3133-3136	the	_
20-23	3137-3146	MINI-Plus	_
20-24	3147-3148	.	_

21-1	3149-3161	Participants	_
21-2	3162-3166	were	_
21-3	3167-3175	excluded	_
21-4	3176-3178	if	_
21-5	3179-3183	they	_
21-6	3184-3187	had	_
21-7	3188-3189	a	_
21-8	3190-3197	current	_
21-9	3198-3207	diagnosis	_
21-10	3208-3210	of	_
21-11	3211-3220	substance	_
21-12	3221-3226	abuse	_
21-13	3227-3229	or	_
21-14	3230-3240	dependence	_
21-15	3241-3242	,	_
21-16	3243-3244	a	_
21-17	3245-3252	history	_
21-18	3253-3255	of	_
21-19	3256-3266	clinically	_
21-20	3267-3278	significant	_
21-21	3279-3287	physical	_
21-22	3288-3295	illness	_
21-23	3296-3297	,	_
21-24	3298-3300	or	_
21-25	3301-3306	metal	_
21-26	3307-3315	implants	_
21-27	3316-3326	precluding	_
21-28	3327-3330	the	_
21-29	3331-3338	ability	_
21-30	3339-3341	to	_
21-31	3342-3344	be	_
21-32	3345-3352	scanned	_
21-33	3353-3357	with	_
21-34	3358-3361	MRI	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging
21-35	3362-3363	.	_

22-1	3364-3366	At	_
22-2	3367-3376	inclusion	_
22-3	3377-3380	and	_
22-4	3381-3387	before	_
22-5	3388-3391	the	_
22-6	3392-3395	PET	http://maven.renci.org/NeuroBridge/neurobridge#PositronEmissionTomography
22-7	3396-3400	scan	http://maven.renci.org/NeuroBridge/neurobridge#PositronEmissionTomography
22-8	3401-3402	,	_
22-9	3403-3415	participants	_
22-10	3416-3420	were	_
22-11	3421-3429	required	_
22-12	3430-3432	to	_
22-13	3433-3437	have	_
22-14	3438-3439	a	_
22-15	3440-3448	negative	_
22-16	3449-3454	urine	_
22-17	3455-3461	screen	_
22-18	3462-3465	for	_
22-19	3466-3471	drugs	_
22-20	3472-3474	of	_
22-21	3475-3480	abuse	_
22-22	3481-3487	and/or	_
22-23	3488-3497	pregnancy	_
22-24	3498-3499	.	_

23-1	3500-3503	All	_
23-2	3504-3516	participants	_
23-3	3517-3525	provided	_
23-4	3526-3533	written	_
23-5	3534-3542	informed	_
23-6	3543-3550	consent	_
23-7	3551-3552	.	_

24-1	3553-3556	The	_
24-2	3557-3564	average	_
24-3	3565-3568	age	_
24-4	3569-3571	of	_
24-5	3572-3579	illness	_
24-6	3580-3585	onset	_
24-7	3586-3589	for	_
24-8	3590-3593	the	_
24-9	3594-3601	patient	_
24-10	3602-3608	sample	_
24-11	3609-3612	was	_
24-12	3613-3618	24.42	_
24-13	3619-3620	±	_
24-14	3621-3625	6.75	_
24-15	3626-3627	(	_
24-16	3628-3633	range	_
24-17	3634-3635	:	_
24-18	3636-3641	17–42	_
24-19	3642-3643	)	_
24-20	3644-3645	,	_
24-21	3646-3650	with	_
24-22	3651-3653	an	_
24-23	3654-3661	average	_
24-24	3662-3670	duration	_
24-25	3671-3673	of	_
24-26	3674-3681	illness	_
24-27	3682-3684	of	_
24-28	3685-3690	16.33	_
24-29	3691-3692	±	_
24-30	3693-3698	14.74	_
24-31	3699-3700	(	_
24-32	3701-3706	range	_
24-33	3707-3708	:	_
24-34	3709-3713	2–48	_
24-35	3714-3715	)	_
24-36	3716-3722	months	_
24-37	3723-3724	.	_

25-1	3725-3728	2.2	_
25-2	3729-3730	.	_

26-1	3731-3732	[	_
26-2	3733-3736	11C	_
26-3	3737-3738	]	_
26-4	3739-3740	-	_
26-5	3741-3742	(	_
26-6	3743-3744	+	_
26-7	3745-3746	)	_
26-8	3747-3752	-PHNO	_
26-9	3753-3762	synthesis	_
26-10	3763-3764	&	_
26-11	3765-3776	acquisition	_
26-12	3777-3778	A	_
26-13	3779-3783	full	_
26-14	3784-3795	description	_
26-15	3796-3798	of	_
26-16	3799-3802	the	_
26-17	3803-3817	radiosynthesis	_
26-18	3818-3820	of	_
26-19	3821-3822	[	_
26-20	3823-3826	11C	_
26-21	3827-3828	]	_
26-22	3829-3830	-	_
26-23	3831-3832	(	_
26-24	3833-3834	+	_
26-25	3835-3836	)	_
26-26	3837-3842	-PHNO	_
26-27	3843-3844	,	_
26-28	3845-3847	as	_
26-29	3848-3852	well	_
26-30	3853-3855	as	_
26-31	3856-3859	how	_
26-32	3860-3863	PET	http://maven.renci.org/NeuroBridge/neurobridge#PositronEmissionTomography
26-33	3864-3870	images	http://maven.renci.org/NeuroBridge/neurobridge#PositronEmissionTomography
26-34	3871-3875	were	_
26-35	3876-3884	acquired	_
26-36	3885-3886	,	_
26-37	3887-3890	can	_
26-38	3891-3893	be	_
26-39	3894-3899	found	_
26-40	3900-3902	in	_
26-41	3903-3911	previous	_
26-42	3912-3924	publications	_
26-43	3925-3926	.	_

27-1	3927-3934	Briefly	_
27-2	3935-3936	,	_
27-3	3937-3938	[	_
27-4	3939-3942	11C	_
27-5	3943-3944	]	_
27-6	3945-3955	-propionyl	_
27-7	3956-3964	chloride	_
27-8	3965-3968	was	_
27-9	3969-3976	reacted	_
27-10	3977-3981	with	_
27-11	3982-4005	9-hydroxynaph-thoxazine	_
27-12	4006-4008	to	_
27-13	4009-4017	generate	_
27-14	4018-4019	a	_
27-15	4020-4021	[	_
27-16	4022-4025	11C	_
27-17	4026-4027	]	_
27-18	4028-4034	-amide	_
27-19	4035-4036	.	_

28-1	4037-4041	This	_
28-2	4042-4045	was	_
28-3	4046-4058	subsequently	_
28-4	4059-4066	reduced	_
28-5	4067-4069	by	_
28-6	4070-4077	lithium	_
28-7	4078-4087	aluminium	_
28-8	4088-4095	hydride	_
28-9	4096-4097	.	_

29-1	4098-4110	Purification	_
29-2	4111-4113	by	_
29-3	4114-4118	HPLC	_
29-4	4119-4122	and	_
29-5	4123-4134	formulation	_
29-6	4135-4139	gave	_
29-7	4140-4156	radio-chemically	_
29-8	4157-4161	pure	_
29-9	4162-4163	[	_
29-10	4164-4167	11C	_
29-11	4168-4169	]	_
29-12	4170-4171	-	_
29-13	4172-4173	(	_
29-14	4174-4175	+	_
29-15	4176-4177	)	_
29-16	4178-4183	-PHNO	_
29-17	4184-4186	as	_
29-18	4187-4188	a	_
29-19	4189-4196	sterile	_
29-20	4197-4198	,	_
29-21	4199-4211	pyrogen-free	_
29-22	4212-4220	solution	_
29-23	4221-4222	.	_

30-1	4223-4226	PET	http://maven.renci.org/NeuroBridge/neurobridge#PositronEmissionTomography
30-2	4227-4233	images	http://maven.renci.org/NeuroBridge/neurobridge#PositronEmissionTomography
30-3	4234-4238	were	_
30-4	4239-4247	acquired	_
30-5	4248-4253	using	_
30-6	4254-4255	a	_
30-7	4256-4271	high-resolution	_
30-8	4272-4286	head-dedicated	_
30-9	4287-4290	PET	http://maven.renci.org/NeuroBridge/neurobridge#PositronEmissionTomography
30-10	4291-4297	camera	http://maven.renci.org/NeuroBridge/neurobridge#PositronEmissionTomography
30-11	4298-4304	system	http://maven.renci.org/NeuroBridge/neurobridge#PositronEmissionTomography
30-12	4305-4306	(	_
30-13	4307-4315	CPS-HRRT	_
30-14	4316-4317	;	_
30-15	4318-4325	Siemens	_
30-16	4326-4335	Molecular	_
30-17	4336-4343	Imaging	_
30-18	4344-4345	,	_
30-19	4346-4349	USA	_
30-20	4350-4351	)	_
30-21	4352-4353	.	_

31-1	4354-4357	The	_
31-2	4358-4366	CPS-HRRT	http://maven.renci.org/NeuroBridge/neurobridge#Thing
31-3	4367-4375	measures	_
31-4	4376-4389	radioactivity	_
31-5	4390-4392	in	_
31-6	4393-4396	207	_
31-7	4397-4402	brain	_
31-8	4403-4409	slices	_
31-9	4410-4411	,	_
31-10	4412-4416	each	_
31-11	4417-4421	with	_
31-12	4422-4423	a	_
31-13	4424-4433	thickness	_
31-14	4434-4436	of	_
31-15	4437-4440	1.2	_
31-16	4441-4443	mm	_
31-17	4444-4445	.	_

32-1	4446-4449	The	_
32-2	4450-4458	in-plane	_
32-3	4459-4469	resolution	_
32-4	4470-4473	was	_
32-5	4474-4487	approximately	_
32-6	4488-4491	2.8	_
32-7	4492-4494	mm	_
32-8	4495-4505	full-width	_
32-9	4506-4508	at	_
32-10	4509-4521	half-maximum	_
32-11	4522-4523	(	_
32-12	4524-4528	FWHM	_
32-13	4529-4530	)	_
32-14	4531-4532	.	_

33-1	4533-4540	Notably	_
33-2	4541-4542	,	_
33-3	4543-4554	significant	_
33-4	4555-4556	[	_
33-5	4557-4560	11C	_
33-6	4561-4562	]	_
33-7	4563-4564	-	_
33-8	4565-4566	(	_
33-9	4567-4568	+	_
33-10	4569-4570	)	_
33-11	4571-4576	-PHNO	_
33-12	4577-4583	uptake	_
33-13	4584-4588	into	_
33-14	4589-4592	the	_
33-15	4593-4599	retina	_
33-16	4600-4605	could	_
33-17	4606-4609	not	_
33-18	4610-4612	be	_
33-19	4613-4621	observed	_
33-20	4622-4624	on	_
33-21	4625-4630	scans	_
33-22	4631-4640	collected	_
33-23	4641-4646	using	_
33-24	4647-4648	a	_
33-25	4649-4664	high-resolution	_
33-26	4665-4668	PET	http://maven.renci.org/NeuroBridge/neurobridge#PositronEmissionTomography
33-27	4669-4671	CT	http://maven.renci.org/NeuroBridge/neurobridge#PositronEmissionTomography
33-28	4672-4673	,	_
33-29	4674-4690	Siemens-Biograph	_
33-30	4691-4696	HiRez	_
33-31	4697-4700	XVI	_
33-32	4701-4702	(	_
33-33	4703-4710	Siemens	_
33-34	4711-4720	Molecular	_
33-35	4721-4728	Imaging	_
33-36	4729-4730	,	_
33-37	4731-4740	Knoxville	_
33-38	4741-4742	,	_
33-39	4743-4745	TN	_
33-40	4746-4747	,	_
33-41	4748-4751	USA	_
33-42	4752-4753	)	_
33-43	4754-4763	operating	_
33-44	4764-4766	in	_
33-45	4767-4769	3D	_
33-46	4770-4774	mode	_
33-47	4775-4779	with	_
33-48	4780-4782	an	_
33-49	4783-4791	in-plane	_
33-50	4792-4802	resolution	_
33-51	4803-4805	of	_
33-52	4806-4819	approximately	_
33-53	4820-4823	4.6	_
33-54	4824-4826	mm	_
33-55	4827-4831	FWHM	_
33-56	4832-4833	(	_
33-57	4834-4840	almost	_
33-58	4841-4845	half	_
33-59	4846-4849	the	_
33-60	4850-4860	resolution	_
33-61	4861-4863	of	_
33-62	4864-4867	the	_
33-63	4868-4876	CPS-HRRT	_
33-64	4877-4878	)	_
33-65	4879-4880	.	_

34-1	4881-4885	Thus	_
34-2	4886-4887	,	_
34-3	4888-4891	PET	http://maven.renci.org/NeuroBridge/neurobridge#PositronEmissionTomography
34-4	4892-4898	camera	_
34-5	4899-4906	systems	_
34-6	4907-4909	of	_
34-7	4910-4914	~2.8	_
34-8	4915-4917	mm	_
34-9	4918-4922	FWHM	_
34-10	4923-4925	or	_
34-11	4926-4932	better	_
34-12	4933-4936	are	_
34-13	4937-4943	likely	_
34-14	4944-4952	required	_
34-15	4953-4955	to	_
34-16	4956-4960	have	_
34-17	4961-4964	the	_
34-18	4965-4976	appropriate	_
34-19	4977-4987	resolution	_
34-20	4988-4990	to	_
34-21	4991-4996	image	_
34-22	4997-4998	[	_
34-23	4999-5002	11C	_
34-24	5003-5004	]	_
34-25	5005-5006	-	_
34-26	5007-5008	(	_
34-27	5009-5010	+	_
34-28	5011-5012	)	_
34-29	5013-5018	-PHNO	_
34-30	5019-5025	uptake	_
34-31	5026-5030	into	_
34-32	5031-5034	the	_
34-33	5035-5041	retina	_
34-34	5042-5043	.	_

35-1	5044-5056	Transmission	_
35-2	5057-5062	scans	_
35-3	5063-5067	were	_
35-4	5068-5076	acquired	_
35-5	5077-5082	using	_
35-6	5083-5084	a	_
35-7	5085-5090	137Cs	_
35-8	5091-5092	(	_
35-9	5093-5102	T1/2=30.2	_
35-10	5103-5105	yr	_
35-11	5106-5107	,	_
35-12	5108-5113	E=662	_
35-13	5114-5117	KeV	_
35-14	5118-5119	)	_
35-15	5120-5126	single	_
35-16	5127-5133	photon	_
35-17	5134-5139	point	_
35-18	5140-5146	source	_
35-19	5147-5149	to	_
35-20	5150-5157	provide	_
35-21	5158-5169	attenuation	_
35-22	5170-5180	correction	_
35-23	5181-5182	,	_
35-24	5183-5186	and	_
35-25	5187-5190	the	_
35-26	5191-5199	emission	_
35-27	5200-5204	data	_
35-28	5205-5209	were	_
35-29	5210-5218	acquired	_
35-30	5219-5221	in	_
35-31	5222-5226	list	_
35-32	5227-5231	mode	_
35-33	5232-5233	.	_

36-1	5234-5237	The	_
36-2	5238-5241	raw	_
36-3	5242-5246	data	_
36-4	5247-5251	were	_
36-5	5252-5265	reconstructed	_
36-6	5266-5268	by	_
36-7	5269-5282	filtered-back	_
36-8	5283-5293	projection	_
36-9	5294-5297	and	_
36-10	5298-5301	the	_
36-11	5302-5310	emission	_
36-12	5311-5315	data	_
36-13	5316-5320	were	_
36-14	5321-5330	re-binned	_
36-15	5331-5335	into	_
36-16	5336-5337	a	_
36-17	5338-5344	series	_
36-18	5345-5347	of	_
36-19	5348-5350	3D	_
36-20	5351-5360	sonograms	_
36-21	5361-5362	.	_

37-1	5363-5371	Scanning	_
37-2	5372-5376	time	_
37-3	5377-5380	was	_
37-4	5381-5387	90-min	_
37-5	5388-5390	in	_
37-6	5391-5397	length	_
37-7	5398-5399	,	_
37-8	5400-5407	wherein	_
37-9	5408-5410	30	_
37-10	5411-5417	frames	_
37-11	5418-5422	were	_
37-12	5423-5430	defined	_
37-13	5431-5432	:	_
37-14	5433-5434	1	_
37-15	5435-5437	to	_
37-16	5438-5440	15	_
37-17	5441-5443	of	_
37-18	5444-5449	1-min	_
37-19	5450-5458	duration	_
37-20	5459-5462	and	_
37-21	5463-5465	16	_
37-22	5466-5468	to	_
37-23	5469-5471	30	_
37-24	5472-5474	of	_
37-25	5475-5480	5-min	_
37-26	5481-5489	duration	_
37-27	5490-5491	.	_

38-1	5492-5493	A	_
38-2	5494-5507	custom-fitted	_
38-3	5508-5521	thermoplastic	_
38-4	5522-5526	mask	_
38-5	5527-5528	(	_
38-6	5529-5537	Tru-Scan	_
38-7	5538-5545	Imaging	_
38-8	5546-5547	,	_
38-9	5548-5557	Annapolis	_
38-10	5558-5559	)	_
38-11	5560-5563	was	_
38-12	5564-5571	created	_
38-13	5572-5575	for	_
38-14	5576-5580	each	_
38-15	5581-5588	subject	_
38-16	5589-5592	and	_
38-17	5593-5597	used	_
38-18	5598-5602	with	_
38-19	5603-5604	a	_
38-20	5605-5609	head	_
38-21	5610-5618	fixation	_
38-22	5619-5625	system	_
38-23	5626-5632	during	_
38-24	5633-5636	PET	http://maven.renci.org/NeuroBridge/neurobridge#PositronEmissionTomography
38-25	5637-5642	scans	_
38-26	5643-5645	to	_
38-27	5646-5652	reduce	_
38-28	5653-5661	movement	_
38-29	5662-5668	during	_
38-30	5669-5672	the	_
38-31	5673-5684	acquisition	_
38-32	5685-5686	.	_

39-1	5687-5688	[	_
39-2	5689-5692	11C	_
39-3	5693-5694	]	_
39-4	5695-5696	-	_
39-5	5697-5698	(	_
39-6	5699-5700	+	_
39-7	5701-5702	)	_
39-8	5703-5708	-PHNO	_
39-9	5709-5712	was	_
39-10	5713-5721	injected	_
39-11	5722-5724	as	_
39-12	5725-5726	a	_
39-13	5727-5732	bolus	_
39-14	5733-5741	followed	_
39-15	5742-5744	by	_
39-16	5745-5746	a	_
39-17	5747-5752	flush	_
39-18	5753-5755	of	_
39-19	5756-5757	2	_
39-20	5758-5760	mL	_
39-21	5761-5767	saline	_
39-22	5768-5772	into	_
39-23	5773-5775	an	_
39-24	5776-5787	intravenous	_
39-25	5788-5792	line	_
39-26	5793-5799	placed	_
39-27	5800-5802	in	_
39-28	5803-5805	an	_
39-29	5806-5817	antecubital	_
39-30	5818-5822	vein	_
39-31	5823-5824	.	_

40-1	5825-5828	The	_
40-2	5829-5833	mean	_
40-3	5834-5847	radioactivity	_
40-4	5848-5852	dose	_
40-5	5853-5856	was	_
40-6	5857-5861	9.38	_
40-7	5862-5863	(	_
40-8	5864-5869	±1.34	_
40-9	5870-5871	)	_
40-10	5872-5875	mCi	_
40-11	5876-5877	,	_
40-12	5878-5882	with	_
40-13	5883-5884	a	_
40-14	5885-5893	specific	_
40-15	5894-5902	activity	_
40-16	5903-5905	of	_
40-17	5906-5913	1160.82	_
40-18	5914-5915	(	_
40-19	5916-5923	±401.58	_
40-20	5924-5925	)	_
40-21	5926-5934	mCi/µmol	_
40-22	5935-5936	,	_
40-23	5937-5939	an	_
40-24	5940-5948	injected	_
40-25	5949-5953	mass	_
40-26	5954-5956	of	_
40-27	5957-5961	2.07	_
40-28	5962-5963	(	_
40-29	5964-5969	±0.46	_
40-30	5970-5971	)	_
40-31	5972-5974	µg	_
40-32	5975-5976	,	_
40-33	5977-5980	and	_
40-34	5981-5983	an	_
40-35	5984-5992	injected	_
40-36	5993-5997	mass	_
40-37	5998-6001	per	_
40-38	6002-6010	kilogram	_
40-39	6011-6013	of	_
40-40	6014-6018	0.03	_
40-41	6019-6020	(	_
40-42	6021-6027	±0.008	_
40-43	6028-6029	)	_
40-44	6030-6035	µg/Kg	_
40-45	6036-6037	.	_

41-1	6038-6042	None	_
41-2	6043-6045	of	_
41-3	6046-6049	the	_
41-4	6050-6062	participants	_
41-5	6063-6071	included	_
41-6	6072-6074	in	_
41-7	6075-6079	this	_
41-8	6080-6086	sample	_
41-9	6087-6095	reported	_
41-10	6096-6102	nausea	_
41-11	6103-6113	associated	_
41-12	6114-6118	with	_
41-13	6119-6120	[	_
41-14	6121-6124	11C	_
41-15	6125-6126	]	_
41-16	6127-6128	-	_
41-17	6129-6130	(	_
41-18	6131-6132	+	_
41-19	6133-6134	)	_
41-20	6135-6140	-PHNO	_
41-21	6141-6150	injection	_
41-22	6151-6152	.	_

42-1	6153-6156	2.3	_
42-2	6157-6158	.	_

43-1	6159-6162	MRI	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging
43-2	6163-6170	imaging	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging
43-3	6171-6179	Subjects	_
43-4	6180-6188	provided	_
43-5	6189-6190	a	_
43-6	6191-6202	T1-weighted	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging
43-7	6203-6206	MRI	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging
43-8	6207-6212	image	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging
43-9	6213-6214	(	_
43-10	6215-6220	TE=17	_
43-11	6221-6222	,	_
43-12	6223-6230	TR=6000	_
43-13	6231-6232	,	_
43-14	6233-6239	FOV=22	_
43-15	6240-6242	cm	_
43-16	6243-6245	2D	_
43-17	6246-6247	,	_
43-18	6248-6255	256×256	_
43-19	6256-6257	,	_
43-20	6258-6263	slice	_
43-21	6264-6273	thickness	_
43-22	6274-6276	of	_
43-23	6277-6278	2	_
43-24	6279-6281	mm	_
43-25	6282-6283	,	_
43-26	6284-6289	NEX=2	_
43-27	6290-6291	)	_
43-28	6292-6300	acquired	_
43-29	6301-6303	on	_
43-30	6304-6305	a	_
43-31	6306-6309	1.5	_
43-32	6310-6311	T	_
43-33	6312-6317	Signa	_
43-34	6318-6325	scanner	_
43-35	6326-6327	(	_
43-36	6328-6335	General	_
43-37	6336-6344	Electric	_
43-38	6345-6352	Medical	_
43-39	6353-6360	Systems	_
43-40	6361-6362	,	_
43-41	6363-6372	Milwaukee	_
43-42	6373-6374	,	_
43-43	6375-6377	WI	_
43-44	6378-6379	)	_
43-45	6380-6381	.	_

44-1	6382-6387	These	_
44-2	6388-6394	images	_
44-3	6395-6399	were	_
44-4	6400-6404	used	_
44-5	6405-6407	to	_
44-6	6408-6415	enhance	_
44-7	6416-6419	the	_
44-8	6420-6428	analysis	_
44-9	6429-6431	of	_
44-10	6432-6435	PET	http://maven.renci.org/NeuroBridge/neurobridge#PositronEmissionTomography
44-11	6436-6441	scans	_
44-12	6442-6443	,	_
44-13	6444-6447	via	_
44-14	6448-6463	co-registration	_
44-15	6464-6465	(	_
44-16	6466-6475	described	_
44-17	6476-6478	in	_
44-18	6479-6485	detail	_
44-19	6486-6491	below	_
44-20	6492-6493	,	_
44-21	6494-6499	under	_
44-22	6500-6501	[	_
44-23	6502-6505	11C	_
44-24	6506-6507	]	_
44-25	6508-6509	-	_
44-26	6510-6511	(	_
44-27	6512-6513	+	_
44-28	6514-6515	)	_
44-29	6516-6521	-PHNO	_
44-30	6522-6527	Image	_
44-31	6528-6536	Analyses	_
44-32	6537-6538	)	_
44-33	6539-6540	.	_

45-1	6541-6544	2.4	_
45-2	6545-6546	.	_

46-1	6547-6548	[	_
46-2	6549-6552	11C	_
46-3	6553-6554	]	_
46-4	6555-6556	-	_
46-5	6557-6558	(	_
46-6	6559-6560	+	_
46-7	6561-6562	)	_
46-8	6563-6568	-PHNO	_
46-9	6569-6574	Image	_
46-10	6575-6583	Analyses	_
46-11	6584-6587	Two	_
46-12	6588-6601	complementary	_
46-13	6602-6612	approaches	_
46-14	6613-6617	were	_
46-15	6618-6626	employed	_
46-16	6627-6630	for	_
46-17	6631-6642	quantifying	_
46-18	6643-6644	[	_
46-19	6645-6648	11C	_
46-20	6649-6650	]	_
46-21	6651-6652	-	_
46-22	6653-6654	(	_
46-23	6655-6656	+	_
46-24	6657-6658	)	_
46-25	6659-6664	-PHNO	_
46-26	6665-6672	binding	_
46-27	6673-6675	in	_
46-28	6676-6679	the	_
46-29	6680-6686	retina	_
46-30	6687-6688	.	_

47-1	6689-6692	For	_
47-2	6693-6696	the	_
47-3	6697-6702	first	_
47-4	6703-6711	approach	_
47-5	6712-6713	(	_
47-6	6714-6720	termed	_
47-7	6721-6722	“	_
47-8	6723-6729	manual	_
47-9	6730-6731	”	_
47-10	6732-6733	)	_
47-11	6734-6735	,	_
47-12	6736-6742	retina	_
47-13	6743-6747	ROIs	_
47-14	6748-6752	were	_
47-15	6753-6758	drawn	_
47-16	6759-6767	manually	_
47-17	6768-6770	on	_
47-18	6771-6775	each	_
47-19	6776-6784	subjects	_
47-20	6785-6793	averaged	_
47-21	6794-6801	dynamic	_
47-22	6802-6803	[	_
47-23	6804-6807	11C	_
47-24	6808-6809	]	_
47-25	6810-6811	-	_
47-26	6812-6813	(	_
47-27	6814-6815	+	_
47-28	6816-6817	)	_
47-29	6818-6823	-PHNO	_
47-30	6824-6829	image	_
47-31	6830-6832	in	_
47-32	6833-6845	native-space	_
47-33	6846-6847	(	_
47-34	6848-6850	on	_
47-35	6851-6856	every	_
47-36	6857-6862	slice	_
47-37	6863-6868	where	_
47-38	6869-6872	the	_
47-39	6873-6879	retina	_
47-40	6880-6885	could	_
47-41	6886-6888	be	_
47-42	6889-6897	observed	_
47-43	6898-6899	)	_
47-44	6900-6901	,	_
47-45	6902-6911	employing	_
47-46	6912-6920	previous	_
47-47	6921-6924	PET	_
47-48	6925-6935	guidelines	_
47-49	6936-6937	(	_
47-50	6938-6941	See	_
47-51	6942-6945	Fig	_
47-52	6946-6947	.	_

48-1	6948-6949	2	_
48-2	6950-6951	)	_
48-3	6952-6953	.	_

49-1	6954-6959	These	_
49-2	6960-6968	manually	_
49-3	6969-6974	drawn	_
49-4	6975-6979	ROIs	_
49-5	6980-6984	were	_
49-6	6985-6989	then	_
49-7	6990-6994	used	_
49-8	6995-6997	to	_
49-9	6998-7005	extract	_
49-10	7006-7010	time	_
49-11	7011-7019	activity	_
49-12	7020-7026	curves	_
49-13	7027-7031	from	_
49-14	7032-7036	each	_
49-15	7037-7045	subjects	_
49-16	7046-7047	'	_
49-17	7048-7055	dynamic	_
49-18	7056-7059	PET	_
49-19	7060-7065	image	_
49-20	7066-7068	in	_
49-21	7069-7081	native-space	_
49-22	7082-7083	(	_
49-23	7084-7087	See	_
49-24	7088-7091	Fig	_
49-25	7092-7093	.	_

50-1	7094-7095	3	_
50-2	7096-7097	)	_
50-3	7098-7099	.	_

51-1	7100-7104	This	_
51-2	7105-7108	was	_
51-3	7109-7113	done	_
51-4	7114-7118	with	_
51-5	7119-7128	reference	_
51-6	7129-7131	to	_
51-7	7132-7136	each	_
51-8	7137-7145	subjects	_
51-9	7146-7159	co-registered	_
51-10	7160-7171	T1-weighted	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging
51-11	7172-7175	MRI	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging
51-12	7176-7181	image	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging
51-13	7182-7183	,	_
51-14	7184-7186	to	_
51-15	7187-7194	confirm	_
51-16	7195-7198	the	_
51-17	7199-7208	placement	_
51-18	7209-7211	of	_
51-19	7212-7215	the	_
51-20	7216-7222	retina	_
51-21	7223-7227	ROIs	_
51-22	7228-7229	.	_

52-1	7230-7233	The	_
52-2	7234-7249	co-registration	_
52-3	7250-7252	of	_
52-4	7253-7257	each	_
52-5	7258-7266	subjects	_
52-6	7267-7270	MRI	_
52-7	7271-7273	to	_
52-8	7274-7277	PET	http://maven.renci.org/NeuroBridge/neurobridge#PositronEmissionTomography
52-9	7278-7283	space	_
52-10	7284-7287	was	_
52-11	7288-7292	done	_
52-12	7293-7298	using	_
52-13	7299-7302	the	_
52-14	7303-7313	normalized	_
52-15	7314-7320	mutual	_
52-16	7321-7332	information	_
52-17	7333-7342	algorithm	_
52-18	7343-7345	as	_
52-19	7346-7357	implemented	_
52-20	7358-7360	in	_
52-21	7361-7365	SPM2	_
52-22	7366-7367	(	_
52-23	7368-7372	SPM2	_
52-24	7373-7374	,	_
52-25	7375-7383	Wellcome	_
52-26	7384-7394	Department	_
52-27	7395-7397	of	_
52-28	7398-7407	Cognitive	_
52-29	7408-7417	Neurology	_
52-30	7418-7419	,	_
52-31	7420-7426	London	_
52-32	7427-7428	;	_
52-33	7429-7433	http	_
52-34	7434-7435	:	_
52-35	7436-7463	//www.fil.ion.ucl.ac.uk/spm	_
52-36	7464-7465	)	_
52-37	7466-7467	.	_

53-1	7468-7471	The	_
53-2	7472-7476	TACs	_
53-3	7477-7481	from	_
53-4	7482-7485	the	_
53-5	7486-7494	manually	_
53-6	7495-7500	drawn	_
53-7	7501-7507	retina	_
53-8	7508-7512	ROIs	_
53-9	7513-7517	were	_
53-10	7518-7526	analyzed	_
53-11	7527-7532	using	_
53-12	7533-7537	both	_
53-13	7538-7541	the	_
53-14	7542-7552	Simplified	_
53-15	7553-7562	Reference	_
53-16	7563-7569	Tissue	_
53-17	7570-7576	Method	_
53-18	7577-7578	(	_
53-19	7579-7583	SRTM	_
53-20	7584-7585	)	_
53-21	7586-7589	and	_
53-22	7590-7596	Ichise	_
53-23	7597-7599	's	_
53-24	7600-7611	Multilinear	_
53-25	7612-7621	Reference	_
53-26	7622-7628	Tissue	_
53-27	7629-7634	Model	_
53-28	7635-7636	(	_
53-29	7637-7641	MRTM	_
53-30	7642-7643	)	_
53-31	7644-7645	,	_
53-32	7646-7650	both	_
53-33	7651-7653	of	_
53-34	7654-7659	which	_
53-35	7660-7664	have	_
53-36	7665-7669	been	_
53-37	7670-7679	validated	_
53-38	7680-7683	for	_
53-39	7684-7687	use	_
53-40	7688-7692	with	_
53-41	7693-7694	[	_
53-42	7695-7698	11C	_
53-43	7699-7700	]	_
53-44	7701-7702	-	_
53-45	7703-7704	(	_
53-46	7705-7706	+	_
53-47	7707-7708	)	_
53-48	7709-7714	-PHNO	_
53-49	7715-7716	.	_

54-1	7717-7720	For	_
54-2	7721-7725	both	_
54-3	7726-7732	models	_
54-4	7733-7734	,	_
54-5	7735-7738	the	_
54-6	7739-7749	cerebellum	_
54-7	7750-7753	was	_
54-8	7754-7758	used	_
54-9	7759-7761	as	_
54-10	7762-7765	the	_
54-11	7766-7775	reference	_
54-12	7776-7782	region	_
54-13	7783-7785	to	_
54-14	7786-7792	derive	_
54-15	7793-7794	a	_
54-16	7795-7807	quantitative	_
54-17	7808-7816	estimate	_
54-18	7817-7819	of	_
54-19	7820-7827	binding	_
54-20	7828-7829	–	_
54-21	7830-7837	binding	_
54-22	7838-7847	potential	_
54-23	7848-7856	relative	_
54-24	7857-7859	to	_
54-25	7860-7863	the	_
54-26	7864-7880	non-displaceable	_
54-27	7881-7892	compartment	_
54-28	7893-7894	(	_
54-29	7895-7899	BPND	_
54-30	7900-7901	)	_
54-31	7902-7903	–	_
54-32	7904-7906	as	_
54-33	7907-7914	defined	_
54-34	7915-7917	by	_
54-35	7918-7921	the	_
54-36	7922-7931	consensus	_
54-37	7932-7944	nomenclature	_
54-38	7945-7948	for	_
54-39	7949-7951	in	_
54-40	7952-7956	vivo	_
54-41	7957-7964	imaging	_
54-42	7965-7967	of	_
54-43	7968-7978	reversibly	_
54-44	7979-7986	binding	_
54-45	7987-7999	radioligands	_
54-46	8000-8001	.	_

55-1	8002-8004	It	_
55-2	8005-8008	has	_
55-3	8009-8013	been	_
55-4	8014-8019	noted	_
55-5	8020-8023	for	_
55-6	8024-8026	in	_
55-7	8027-8031	vivo	_
55-8	8032-8037	human	_
55-9	8038-8045	studies	_
55-10	8046-8050	with	_
55-11	8051-8052	[	_
55-12	8053-8056	11C	_
55-13	8057-8058	]	_
55-14	8059-8060	-	_
55-15	8061-8062	(	_
55-16	8063-8064	+	_
55-17	8065-8066	)	_
55-18	8067-8072	-PHNO	_
55-19	8073-8077	that	_
55-20	8078-8083	there	_
55-21	8084-8086	is	_
55-22	8087-8088	a	_
55-23	8089-8094	small	_
55-24	8095-8107	displaceable	_
55-25	8108-8114	signal	_
55-26	8115-8117	in	_
55-27	8118-8128	cerebellum	_
55-28	8129-8130	(	_
55-29	8131-8140	BPND=~0.4	_
55-30	8141-8142	)	_
55-31	8143-8155	representing	_
55-32	8156-8163	binding	_
55-33	8164-8166	to	_
55-34	8167-8170	D3R	_
55-35	8171-8173	in	_
55-36	8174-8184	cerebellar	_
55-37	8185-8190	lobes	_
55-38	8191-8193	IX	_
55-39	8194-8197	and	_
55-40	8198-8199	X	_
55-41	8200-8201	.	_

56-1	8202-8206	Thus	_
56-2	8207-8208	,	_
56-3	8209-8214	while	_
56-4	8215-8217	we	_
56-5	8218-8222	have	_
56-6	8223-8227	done	_
56-7	8228-8231	our	_
56-8	8232-8236	best	_
56-9	8237-8239	to	_
56-10	8240-8247	exclude	_
56-11	8248-8253	lobes	_
56-12	8254-8256	IX	_
56-13	8257-8260	and	_
56-14	8261-8262	X	_
56-15	8263-8265	in	_
56-16	8266-8269	our	_
56-17	8270-8280	cerebellar	_
56-18	8281-8284	ROI	_
56-19	8285-8286	,	_
56-20	8287-8292	using	_
56-21	8293-8296	the	_
56-22	8297-8307	cerebellum	_
56-23	8308-8310	as	_
56-24	8311-8314	the	_
56-25	8315-8324	reference	_
56-26	8325-8331	region	_
56-27	8332-8336	with	_
56-28	8337-8338	[	_
56-29	8339-8342	11C	_
56-30	8343-8344	]	_
56-31	8345-8346	-	_
56-32	8347-8348	(	_
56-33	8349-8350	+	_
56-34	8351-8352	)	_
56-35	8353-8358	-PHNO	_
56-36	8359-8362	may	_
56-37	8363-8369	result	_
56-38	8370-8372	in	_
56-39	8373-8377	some	_
56-40	8378-8393	underestimation	_
56-41	8394-8396	of	_
56-42	8397-8401	BPND	_
56-43	8402-8404	at	_
56-44	8405-8408	D3R	_
56-45	8409-8410	.	_

57-1	8411-8419	Moreover	_
57-2	8420-8421	,	_
57-3	8422-8424	we	_
57-4	8425-8434	recognize	_
57-5	8435-8439	that	_
57-6	8440-8443	use	_
57-7	8444-8446	of	_
57-8	8447-8450	the	_
57-9	8451-8455	SRTM	http://maven.renci.org/NeuroBridge/neurobridge#Thing
57-10	8456-8459	and	_
57-11	8460-8464	MRTM	http://maven.renci.org/NeuroBridge/neurobridge#Thing
57-12	8465-8467	is	_
57-13	8468-8478	predicated	_
57-14	8479-8481	on	_
57-15	8482-8485	the	_
57-16	8486-8496	assumption	_
57-17	8497-8501	that	_
57-18	8502-8507	blood	_
57-19	8508-8512	flow	_
57-20	8513-8517	into	_
57-21	8518-8521	and	_
57-22	8522-8525	out	_
57-23	8526-8528	of	_
57-24	8529-8532	the	_
57-25	8533-8539	target	_
57-26	8540-8543	and	_
57-27	8544-8553	reference	_
57-28	8554-8561	regions	_
57-29	8562-8565	are	_
57-30	8566-8573	similar	_
57-31	8574-8575	.	_

58-1	8576-8580	This	_
58-2	8581-8591	assumption	_
58-3	8592-8595	may	_
58-4	8596-8599	not	_
58-5	8600-8602	be	_
58-6	8603-8607	true	_
58-7	8608-8611	for	_
58-8	8612-8616	both	_
58-9	8617-8620	the	_
58-10	8621-8632	blood-brain	_
58-11	8633-8640	barrier	_
58-12	8641-8642	(	_
58-13	8643-8653	cerebellar	_
58-14	8654-8663	reference	_
58-15	8664-8670	region	_
58-16	8671-8672	)	_
58-17	8673-8676	and	_
58-18	8677-8680	the	_
58-19	8681-8693	retina-brain	_
58-20	8694-8701	barrier	_
58-21	8702-8703	(	_
58-22	8704-8710	retina	_
58-23	8711-8717	target	_
58-24	8718-8724	region	_
58-25	8725-8726	)	_
58-26	8727-8728	,	_
58-27	8729-8733	thus	_
58-28	8734-8741	biasing	_
58-29	8742-8745	our	_
58-30	8746-8754	estimate	_
58-31	8755-8757	of	_
58-32	8758-8762	BPND	_
58-33	8763-8764	.	_

59-1	8765-8769	This	_
59-2	8770-8775	poses	_
59-3	8776-8777	a	_
59-4	8778-8788	limitation	_
59-5	8789-8791	in	_
59-6	8792-8806	quantification	_
59-7	8807-8812	which	_
59-8	8813-8816	can	_
59-9	8817-8821	only	_
59-10	8822-8824	be	_
59-11	8825-8832	avoided	_
59-12	8833-8838	using	_
59-13	8839-8847	arterial	_
59-14	8848-8856	sampling	_
59-15	8857-8859	of	_
59-16	8860-8861	[	_
59-17	8862-8865	11C	_
59-18	8866-8867	]	_
59-19	8868-8869	-	_
59-20	8870-8871	(	_
59-21	8872-8873	+	_
59-22	8874-8875	)	_
59-23	8876-8881	-PHNO	_
59-24	8882-8883	,	_
59-25	8884-8889	which	_
59-26	8890-8892	is	_
59-27	8893-8897	both	_
59-28	8898-8906	invasive	_
59-29	8907-8910	and	_
59-30	8911-8917	costly	_
59-31	8918-8919	.	_

60-1	8920-8923	For	_
60-2	8924-8927	the	_
60-3	8928-8934	second	_
60-4	8935-8943	approach	_
60-5	8944-8945	(	_
60-6	8946-8952	termed	_
60-7	8953-8954	“	_
60-8	8955-8964	automated	_
60-9	8965-8966	”	_
60-10	8967-8968	)	_
60-11	8969-8970	,	_
60-12	8971-8974	the	_
60-13	8975-8980	basis	_
60-14	8981-8989	function	_
60-15	8990-9004	implementation	_
60-16	9005-9007	of	_
60-17	9008-9011	the	_
60-18	9012-9016	SRTM	_
60-19	9017-9020	was	_
60-20	9021-9028	applied	_
60-21	9029-9031	to	_
60-22	9032-9035	the	_
60-23	9036-9043	dynamic	_
60-24	9044-9047	PET	http://maven.renci.org/NeuroBridge/neurobridge#PositronEmissionTomography
60-25	9048-9054	images	_
60-26	9055-9057	to	_
60-27	9058-9066	generate	_
60-28	9067-9077	parametric	_
60-29	9078-9088	voxel-wise	_
60-30	9089-9093	BPND	_
60-31	9094-9098	maps	_
60-32	9099-9104	using	_
60-33	9105-9109	PMOD	_
60-34	9110-9111	(	_
60-35	9112-9116	v2.7	_
60-36	9117-9118	,	_
60-37	9119-9123	PMOD	_
60-38	9124-9136	Technologies	_
60-39	9137-9138	,	_
60-40	9139-9145	Zurich	_
60-41	9146-9147	,	_
60-42	9148-9159	Switzerland	_
60-43	9160-9161	)	_
60-44	9162-9163	.	_

61-1	9164-9169	These	_
61-2	9170-9176	images	_
61-3	9177-9181	were	_
61-4	9182-9191	spatially	_
61-5	9192-9202	normalized	_
61-6	9203-9207	into	_
61-7	9208-9211	MNI	_
61-8	9212-9217	brain	_
61-9	9218-9223	space	_
61-10	9224-9226	by	_
61-11	9227-9234	Nearest	_
61-12	9235-9244	Neighbour	_
61-13	9245-9258	Interpolation	_
61-14	9259-9263	with	_
61-15	9264-9265	a	_
61-16	9266-9271	voxel	_
61-17	9272-9276	size	_
61-18	9277-9282	fixed	_
61-19	9283-9285	in	_
61-20	9286-9287	2	_
61-21	9288-9289	×	_
61-22	9290-9291	2	_
61-23	9292-9293	×	_
61-24	9294-9295	2	_
61-25	9296-9299	mm3	_
61-26	9300-9305	using	_
61-27	9306-9310	SPM2	_
61-28	9311-9312	.	_

62-1	9313-9321	Regional	_
62-2	9322-9326	BPND	_
62-3	9327-9336	estimates	_
62-4	9337-9341	were	_
62-5	9342-9346	then	_
62-6	9347-9354	derived	_
62-7	9355-9359	from	_
62-8	9360-9361	a	_
62-9	9362-9370	manually	_
62-10	9371-9376	drawn	_
62-11	9377-9383	retina	_
62-12	9384-9387	ROI	_
62-13	9388-9395	defined	_
62-14	9396-9398	in	_
62-15	9399-9402	MNI	_
62-16	9403-9408	space	_
62-17	9409-9410	.	_

63-1	9411-9414	The	_
63-2	9415-9422	drawing	_
63-3	9423-9425	of	_
63-4	9426-9430	this	_
63-5	9431-9434	ROI	_
63-6	9435-9438	was	_
63-7	9439-9444	aided	_
63-8	9445-9447	by	_
63-9	9448-9461	superimposing	_
63-10	9462-9465	the	_
63-11	9466-9473	average	_
63-12	9474-9476	of	_
63-13	9477-9480	the	_
63-14	9481-9491	parametric	_
63-15	9492-9502	voxel-wise	_
63-16	9503-9507	BPND	_
63-17	9508-9512	maps	_
63-18	9513-9515	of	_
63-19	9516-9519	all	_
63-20	9520-9523	the	_
63-21	9524-9532	subjects	_
63-22	9533-9537	onto	_
63-23	9538-9540	an	_
63-24	9541-9544	MNI	_
63-25	9545-9553	template	_
63-26	9554-9555	.	_

64-1	9556-9559	2.5	_
64-2	9560-9561	.	_

65-1	9562-9573	Post-mortem	_
65-2	9574-9581	retinal	_
65-3	9582-9588	tissue	_
65-4	9589-9596	samples	_
65-5	9597-9608	Post-mortem	_
65-6	9609-9616	retinal	_
65-7	9617-9624	tissues	_
65-8	9625-9629	from	_
65-9	9630-9634	four	_
65-10	9635-9643	patients	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
65-11	9644-9648	with	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
65-12	9649-9662	schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
65-13	9663-9664	,	_
65-14	9665-9668	and	_
65-15	9669-9673	four	_
65-16	9674-9678	age-	_
65-17	9679-9682	and	_
65-18	9683-9694	sex-matched	_
65-19	9695-9702	healthy	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder
65-20	9703-9711	controls	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder
65-21	9712-9713	,	_
65-22	9714-9718	were	_
65-23	9719-9727	acquired	_
65-24	9728-9732	from	_
65-25	9733-9736	the	_
65-26	9737-9740	St.	_
65-27	9741-9748	Michael	_
65-28	9749-9751	's	_
65-29	9752-9760	Hospital	_
65-30	9761-9766	Human	_
65-31	9767-9770	Eye	_
65-32	9771-9778	Biobank	_
65-33	9779-9780	(	_
65-34	9781-9785	http	_
65-35	9786-9787	:	_
65-36	9788-9829	//www.stmichaelshospital.com/eye-biobank/	_
65-37	9830-9831	;	_
65-38	9832-9839	Toronto	_
65-39	9840-9841	,	_
65-40	9842-9849	Ontario	_
65-41	9850-9851	,	_
65-42	9852-9858	Canada	_
65-43	9859-9860	)	_
65-44	9861-9862	(	_
65-45	9863-9866	See	_
65-46	9867-9872	Table	_
65-47	9873-9874	3	_
65-48	9875-9876	)	_
65-49	9877-9878	.	_

66-1	9879-9886	Samples	_
66-2	9887-9891	were	_
66-3	9892-9906	formalin-fixed	_
66-4	9907-9924	paraffin-embedded	_
66-5	9925-9926	(	_
66-6	9927-9931	FFPE	_
66-7	9932-9933	)	_
66-8	9934-9935	.	_

67-1	9936-9939	2.6	_
67-2	9940-9941	.	_

68-1	9942-9948	Sample	_
68-2	9949-9960	preparation	_
68-3	9961-9964	and	_
68-4	9965-9980	high-resolution	_
68-5	9981-9989	parallel	_
68-6	9990-9998	reaction	_
68-7	9999-10009	monitoring	_
68-8	10010-10011	(	_
68-9	10012-10015	PRM	_
68-10	10016-10017	)	_
68-11	10018-10026	analyses	_
68-12	10027-10032	Total	_
68-13	10033-10039	sample	_
68-14	10040-10051	homogenates	_
68-15	10052-10053	(	_
68-16	10054-10060	approx	_
68-17	10061-10062	.	_

69-1	10063-10064	2	_
69-2	10065-10067	µg	_
69-3	10068-10069	)	_
69-4	10070-10074	were	_
69-5	10075-10084	subjected	_
69-6	10085-10087	to	_
69-7	10088-10089	a	_
69-8	10090-10098	modified	_
69-9	10099-10111	filter-aided	_
69-10	10112-10118	sample	_
69-11	10119-10130	preparation	_
69-12	10131-10132	(	_
69-13	10133-10137	FASP	_
69-14	10138-10139	)	_
69-15	10140-10148	protocol	_
69-16	10149-10151	as	_
69-17	10152-10162	previously	_
69-18	10163-10172	described	_
69-19	10173-10174	,	_
69-20	10175-10179	with	_
69-21	10180-10190	additional	_
69-22	10191-10204	precipitation	_
69-23	10205-10210	using	_
69-24	10211-10213	an	_
69-25	10214-10219	equal	_
69-26	10220-10226	volume	_
69-27	10227-10229	of	_
69-28	10230-10232	2M	_
69-29	10233-10236	KCL	_
69-30	10237-10240	for	_
69-31	10241-10250	depletion	_
69-32	10251-10253	of	_
69-33	10254-10262	residual	_
69-34	10263-10273	detergents	_
69-35	10274-10275	.	_

70-1	10276-10281	Lys-C	_
70-2	10282-10285	and	_
70-3	10286-10293	tryptic	_
70-4	10294-10302	peptides	_
70-5	10303-10307	were	_
70-6	10308-10316	combined	_
70-7	10317-10320	and	_
70-8	10321-10330	processed	_
70-9	10331-10333	on	_
70-10	10334-10340	Pierce	_
70-11	10341-10344	C18	_
70-12	10345-10349	Tips	_
70-13	10350-10358	reversed	_
70-14	10359-10364	phase	_
70-15	10365-10370	resin	_
70-16	10371-10372	(	_
70-17	10373-10379	Thermo	_
70-18	10380-10390	Scientific	_
70-19	10391-10392	)	_
70-20	10393-10396	for	_
70-21	10397-10406	desalting	_
70-22	10407-10410	and	_
70-23	10411-10424	concentration	_
70-24	10425-10426	.	_

71-1	10427-10442	High-resolution	_
71-2	10443-10451	parallel	_
71-3	10452-10460	reaction	_
71-4	10461-10471	monitoring	_
71-5	10472-10473	(	_
71-6	10474-10480	HR-PRM	_
71-7	10481-10482	)	_
71-8	10483-10491	analyses	_
71-9	10492-10496	were	_
71-10	10497-10506	performed	_
71-11	10507-10509	on	_
71-12	10510-10511	a	_
71-13	10512-10513	Q	_
71-14	10514-10522	Exactive	_
71-15	10523-10525	HF	_
71-16	10526-10545	quadrupole–orbitrap	_
71-17	10546-10550	mass	_
71-18	10551-10563	spectrometer	_
71-19	10564-10565	(	_
71-20	10566-10572	Thermo	_
71-21	10573-10579	Fisher	_
71-22	10580-10590	Scientific	_
71-23	10591-10592	)	_
71-24	10593-10600	coupled	_
71-25	10601-10603	to	_
71-26	10604-10606	an	_
71-27	10607-10611	EASY	_
71-28	10612-10620	nanoflow	_
71-29	10621-10627	liquid	_
71-30	10628-10642	chromatography	_
71-31	10643-10644	(	_
71-32	10645-10654	EASY-nLC™	_
71-33	10655-10656	)	_
71-34	10657-10663	system	_
71-35	10664-10665	(	_
71-36	10666-10672	Thermo	_
71-37	10673-10679	Fisher	_
71-38	10680-10690	Scientific	_
71-39	10691-10692	)	_
71-40	10693-10694	.	_

72-1	10695-10703	Peptides	_
72-2	10704-10708	were	_
72-3	10709-10718	separated	_
72-4	10719-10721	on	_
72-5	10722-10723	a	_
72-6	10724-10726	50	_
72-7	10727-10729	cm	_
72-8	10730-10736	column	_
72-9	10737-10738	(	_
72-10	10739-10741	75	_
72-11	10742-10744	µm	_
72-12	10745-10750	inner	_
72-13	10751-10759	diameter	_
72-14	10760-10761	)	_
72-15	10762-10768	packed	_
72-16	10769-10773	with	_
72-17	10774-10785	PepMap®RSLC	_
72-18	10786-10789	C18	_
72-19	10790-10795	resin	_
72-20	10796-10798	at	_
72-21	10799-10801	60	_
72-22	10802-10804	°C	_
72-23	10805-10806	,	_
72-24	10807-10812	using	_
72-25	10813-10814	a	_
72-26	10815-10819	flow	_
72-27	10820-10824	rate	_
72-28	10825-10827	of	_
72-29	10828-10831	250	_
72-30	10832-10838	nl/min	_
72-31	10839-10841	on	_
72-32	10842-10843	a	_
72-33	10844-10845	0	_
72-34	10846-10847	%	_
72-35	10848-10851	–42	_
72-36	10852-10853	%	_
72-37	10854-10866	acetonitrile	_
72-38	10867-10868	(	_
72-39	10869-10872	ACN	_
72-40	10873-10874	)	_
72-41	10875-10877	in	_
72-42	10878-10881	0.1	_
72-43	10882-10883	%	_
72-44	10884-10890	formic	_
72-45	10891-10895	acid	_
72-46	10896-10897	(	_
72-47	10898-10900	FA	_
72-48	10901-10902	)	_
72-49	10903-10911	gradient	_
72-50	10912-10915	and	_
72-51	10916-10922	Buffer	_
72-52	10923-10924	B	_
72-53	10925-10926	(	_
72-54	10927-10929	80	_
72-55	10930-10931	%	_
72-56	10932-10935	ACN	_
72-57	10936-10940	with	_
72-58	10941-10944	0.1	_
72-59	10945-10946	%	_
72-60	10947-10949	FA	_
72-61	10950-10951	)	_
72-62	10952-10956	over	_
72-63	10957-10959	60	_
72-64	10960-10963	min	_
72-65	10964-10965	.	_

73-1	10966-10972	Column	_
73-2	10973-10979	washes	_
73-3	10980-10984	were	_
73-4	10985-10994	performed	_
73-5	10995-10997	on	_
73-6	10998-10999	a	_
73-7	11000-11002	30	_
73-8	11003-11004	%	_
73-9	11005-11008	–90	_
73-10	11009-11010	%	_
73-11	11011-11023	acetonitrile	_
73-12	11024-11026	in	_
73-13	11027-11030	0.1	_
73-14	11031-11032	%	_
73-15	11033-11039	formic	_
73-16	11040-11044	acid	_
73-17	11045-11053	gradient	_
73-18	11054-11057	for	_
73-19	11058-11059	2	_
73-20	11060-11063	min	_
73-21	11064-11065	.	_

74-1	11066-11069	The	_
74-2	11070-11076	IonMax	_
74-3	11077-11089	electrospray	_
74-4	11090-11093	ion	_
74-5	11094-11100	source	_
74-6	11101-11109	settings	_
74-7	11110-11114	were	_
74-8	11115-11116	:	_
74-9	11117-11122	spray	_
74-10	11123-11130	voltage	_
74-11	11131-11132	,	_
74-12	11133-11138	+1900	_
74-13	11139-11140	V	_
74-14	11141-11144	and	_
74-15	11145-11154	capillary	_
74-16	11155-11166	temperature	_
74-17	11167-11168	,	_
74-18	11169-11173	+250	_
74-19	11174-11176	°C	_
74-20	11177-11178	.	_

75-1	11179-11181	In	_
75-2	11182-11185	the	_
75-3	11186-11189	PRM	_
75-4	11190-11196	method	_
75-5	11197-11198	,	_
75-6	11199-11201	we	_
75-7	11202-11206	only	_
75-8	11207-11215	observed	_
75-9	11216-11222	charge	_
75-10	11223-11229	states	_
75-11	11230-11232	as	_
75-12	11233-11242	described	_
75-13	11243-11245	in	_
75-14	11246-11249	the	_
75-15	11250-11259	inclusion	_
75-16	11260-11264	list	_
75-17	11265-11268	and	_
75-18	11269-11276	skyline	_
75-19	11277-11281	file	_
75-20	11282-11283	.	_

76-1	11284-11287	The	_
76-2	11288-11296	targeted	_
76-3	11297-11302	MS/MS	_
76-4	11303-11306	was	_
76-5	11307-11310	run	_
76-6	11311-11313	at	_
76-7	11314-11316	an	_
76-8	11317-11325	Orbitrap	_
76-9	11326-11336	resolution	_
76-10	11337-11339	of	_
76-11	11340-11346	30,000	_
76-12	11347-11349	at	_
76-13	11350-11353	m/z	_
76-14	11354-11357	200	_
76-15	11358-11359	,	_
76-16	11360-11362	an	_
76-17	11363-11366	AGC	_
76-18	11367-11373	target	_
76-19	11374-11379	value	_
76-20	11380-11382	of	_
76-21	11383-11384	2	_
76-22	11385-11386	×	_
76-23	11387-11390	105	_
76-24	11391-11392	,	_
76-25	11393-11396	and	_
76-26	11397-11404	maximum	_
76-27	11405-11409	fill	_
76-28	11410-11415	times	_
76-29	11416-11418	of	_
76-30	11419-11422	100	_
76-31	11423-11425	ms	_
76-32	11426-11427	.	_

77-1	11428-11431	The	_
77-2	11432-11440	targeted	_
77-3	11441-11448	peptide	_
77-4	11449-11452	was	_
77-5	11453-11461	isolated	_
77-6	11462-11467	using	_
77-7	11468-11469	a	_
77-8	11470-11473	0.8	_
77-9	11474-11477	m/z	_
77-10	11478-11482	unit	_
77-11	11483-11489	window	_
77-12	11490-11491	.	_

78-1	11492-11505	Fragmentation	_
78-2	11506-11509	was	_
78-3	11510-11519	performed	_
78-4	11520-11524	with	_
78-5	11525-11535	normalized	_
78-6	11536-11545	collision	_
78-7	11546-11552	energy	_
78-8	11553-11554	(	_
78-9	11555-11558	NCE	_
78-10	11559-11560	)	_
78-11	11561-11563	of	_
78-12	11564-11566	32	_
78-13	11567-11569	eV	_
78-14	11570-11571	.	_

79-1	11572-11574	In	_
79-2	11575-11578	the	_
79-3	11579-11582	PRM	_
79-4	11583-11589	method	_
79-5	11590-11591	,	_
79-6	11592-11594	we	_
79-7	11595-11599	only	_
79-8	11600-11608	observed	_
79-9	11609-11615	charge	_
79-10	11616-11622	states	_
79-11	11623-11625	as	_
79-12	11626-11635	described	_
79-13	11636-11638	in	_
79-14	11639-11642	the	_
79-15	11643-11652	inclusion	_
79-16	11653-11657	list	_
79-17	11658-11661	and	_
79-18	11662-11669	skyline	_
79-19	11670-11674	file	_
79-20	11675-11676	.	_

80-1	11677-11682	Seven	_
80-2	11683-11691	peptides	_
80-3	11692-11695	and	_
80-4	11696-11701	their	_
80-5	11702-11715	corresponding	_
80-6	11716-11721	heavy	_
80-7	11722-11730	peptides	_
80-8	11731-11732	(	_
80-9	11733-11738	Table	_
80-10	11739-11740	4	_
80-11	11741-11742	)	_
80-12	11743-11747	were	_
80-13	11748-11757	comprised	_
80-14	11758-11760	in	_
80-15	11761-11764	the	_
80-16	11765-11774	inclusion	_
80-17	11775-11779	list	_
80-18	11780-11781	.	_

81-1	11782-11788	Target	_
81-2	11789-11797	peptides	_
81-3	11798-11802	were	_
81-4	11803-11811	selected	_
81-5	11812-11817	based	_
81-6	11818-11820	on	_
81-7	11821-11823	in	_
81-8	11824-11830	silico	_
81-9	11831-11839	cleavage	_
81-10	11840-11842	of	_
81-11	11843-11846	the	_
81-12	11847-11855	proteins	_
81-13	11856-11861	using	_
81-14	11862-11865	the	_
81-15	11866-11873	Peptide	_
81-16	11874-11878	Mass	_
81-17	11879-11886	feature	_
81-18	11887-11889	of	_
81-19	11890-11896	ExPASy	_
81-20	11897-11911	bioinformatics	_
81-21	11912-11918	portal	_
81-22	11919-11920	(	_
81-23	11921-11925	http	_
81-24	11926-11927	:	_
81-25	11928-11958	//web.expasy.org/peptide_mass/	_
81-26	11959-11960	)	_
81-27	11961-11962	.	_

82-1	11963-11966	The	_
82-2	11967-11976	following	_
82-3	11977-11985	settings	_
82-4	11986-11990	were	_
82-5	11991-11995	used	_
82-6	11996-11997	:	_
82-7	11998-12004	enzyme	_
82-8	12005-12006	(	_
82-9	12007-12014	trypsin	_
82-10	12015-12016	)	_
82-11	12017-12018	;	_
82-12	12019-12020	0	_
82-13	12021-12027	missed	_
82-14	12028-12036	cleavage	_
82-15	12037-12040	and	_
82-16	12041-12048	display	_
82-17	12049-12052	the	_
82-18	12053-12061	peptides	_
82-19	12062-12066	with	_
82-20	12067-12068	a	_
82-21	12069-12073	mass	_
82-22	12074-12080	bigger	_
82-23	12081-12085	than	_
82-24	12086-12089	500	_
82-25	12090-12092	Da	_
82-26	12093-12094	.	_

83-1	12095-12098	2.7	_
83-2	12099-12100	.	_

84-1	12101-12104	PRM	_
84-2	12105-12109	data	_
84-3	12110-12118	analysis	_
84-4	12119-12123	Mass	_
84-5	12124-12136	spectrometry	_
84-6	12137-12145	analysis	_
84-7	12146-12149	was	_
84-8	12150-12159	performed	_
84-9	12160-12162	at	_
84-10	12163-12166	the	_
84-11	12167-12172	SPARC	_
84-12	12173-12182	Biocentre	_
84-13	12183-12184	(	_
84-14	12185-12188	The	_
84-15	12189-12197	Hospital	_
84-16	12198-12201	for	_
84-17	12202-12206	Sick	_
84-18	12207-12215	Children	_
84-19	12216-12217	;	_
84-20	12218-12226	SickKids	_
84-21	12227-12228	,	_
84-22	12229-12236	Toronto	_
84-23	12237-12238	)	_
84-24	12239-12240	.	_

85-1	12241-12243	We	_
85-2	12244-12253	attempted	_
85-3	12254-12256	to	_
85-4	12257-12265	quantify	_
85-5	12266-12267	4	_
85-6	12268-12271	and	_
85-7	12272-12273	3	_
85-8	12274-12280	unique	_
85-9	12281-12289	peptides	_
85-10	12290-12293	for	_
85-11	12294-12297	D2R	_
85-12	12298-12301	and	_
85-13	12302-12305	D3R	_
85-14	12306-12307	,	_
85-15	12308-12320	respectively	_
85-16	12321-12322	(	_
85-17	12323-12326	see	_
85-18	12327-12332	Table	_
85-19	12333-12334	4	_
85-20	12335-12336	)	_
85-21	12337-12338	.	_

86-1	12339-12346	However	_
86-2	12347-12348	,	_
86-3	12349-12356	because	_
86-4	12357-12359	of	_
86-5	12360-12363	the	_
86-6	12364-12374	relatively	_
86-7	12375-12378	low	_
86-8	12379-12386	protein	_
86-9	12387-12392	yield	_
86-10	12393-12395	in	_
86-11	12396-12399	our	_
86-12	12400-12404	FFPE	_
86-13	12405-12410	slide	_
86-14	12411-12418	samples	_
86-15	12419-12420	,	_
86-16	12421-12425	only	_
86-17	12426-12427	a	_
86-18	12428-12434	single	_
86-19	12435-12441	unique	_
86-20	12442-12449	peptide	_
86-21	12450-12452	of	_
86-22	12453-12459	either	_
86-23	12460-12467	protein	_
86-24	12468-12471	was	_
86-25	12472-12480	detected	_
86-26	12481-12484	and	_
86-27	12485-12497	subsequently	_
86-28	12498-12502	used	_
86-29	12503-12506	for	_
86-30	12507-12521	identification	_
86-31	12522-12523	.	_

87-1	12524-12528	Data	_
87-2	12529-12537	analysis	_
87-3	12538-12541	and	_
87-4	12542-12556	quantification	_
87-5	12557-12559	of	_
87-6	12560-12563	PRM	_
87-7	12564-12568	runs	_
87-8	12569-12572	was	_
87-9	12573-12582	performed	_
87-10	12583-12588	using	_
87-11	12589-12596	Skyline	_
87-12	12597-12605	software	_
87-13	12606-12607	.	_

88-1	12608-12616	Relative	_
88-2	12617-12631	quantification	_
88-3	12632-12634	of	_
88-4	12635-12638	D2R	_
88-5	12639-12642	and	_
88-6	12643-12646	D3R	_
88-7	12647-12655	peptides	_
88-8	12656-12660	from	_
88-9	12661-12674	schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
88-10	12675-12682	patient	_
88-11	12683-12686	and	_
88-12	12687-12694	control	_
88-13	12695-12702	samples	_
88-14	12703-12706	was	_
88-15	12707-12712	based	_
88-16	12713-12715	on	_
88-17	12716-12719	the	_
88-18	12720-12723	sum	_
88-19	12724-12726	of	_
88-20	12727-12730	the	_
88-21	12731-12735	area	_
88-22	12736-12741	under	_
88-23	12742-12745	the	_
88-24	12746-12752	curves	_
88-25	12753-12754	(	_
88-26	12755-12758	AUC	_
88-27	12759-12760	)	_
88-28	12761-12763	of	_
88-29	12764-12767	the	_
88-30	12768-12771	top	_
88-31	12772-12777	three	_
88-32	12778-12782	most	_
88-33	12783-12790	intense	_
88-34	12791-12798	peptide	_
88-35	12799-12808	fragments	_
88-36	12809-12810	.	_

89-1	12811-12814	The	_
89-2	12815-12818	use	_
89-3	12819-12821	of	_
89-4	12822-12823	a	_
89-5	12824-12830	subset	_
89-6	12831-12833	of	_
89-7	12834-12839	three	_
89-8	12840-12842	to	_
89-9	12843-12846	six	_
89-10	12847-12855	fragment	_
89-11	12856-12860	ions	_
89-12	12861-12862	(	_
89-13	12863-12867	with	_
89-14	12868-12878	acceptable	_
89-15	12879-12883	peak	_
89-16	12884-12890	purity	_
89-17	12891-12892	)	_
89-18	12893-12896	for	_
89-19	12897-12904	peptide	_
89-20	12905-12917	quantitation	_
89-21	12918-12921	has	_
89-22	12922-12926	been	_
89-23	12927-12937	previously	_
89-24	12938-12947	suggested	_
89-25	12948-12950	to	_
89-26	12951-12956	yield	_
89-27	12957-12961	more	_
89-28	12962-12970	accurate	_
89-29	12971-12978	results	_
89-30	12979-12983	than	_
89-31	12984-12987	the	_
89-32	12988-12994	entire	_
89-33	12995-12998	set	_
89-34	12999-13000	.	_

90-1	13001-13011	Endogenous	_
90-2	13012-13020	peptides	_
90-3	13021-13025	were	_
90-4	13026-13033	matched	_
90-5	13034-13036	to	_
90-6	13037-13042	heavy	_
90-7	13043-13050	isotope	_
90-8	13051-13059	peptides	_
90-9	13060-13065	based	_
90-10	13066-13068	on	_
90-11	13069-13074	their	_
90-12	13075-13082	similar	_
90-13	13083-13092	retention	_
90-14	13093-13098	times	_
90-15	13099-13102	and	_
90-16	13103-13113	transition	_
90-17	13114-13122	patterns	_
90-18	13123-13124	.	_

91-1	13125-13128	2.8	_
91-2	13129-13130	.	_

92-1	13131-13142	Statistical	_
92-2	13143-13151	analyses	_
92-3	13152-13163	Statistical	_
92-4	13164-13172	analyses	_
92-5	13173-13177	were	_
92-6	13178-13187	performed	_
92-7	13188-13193	using	_
92-8	13194-13197	IBM	_
92-9	13198-13202	SPSS	_
92-10	13203-13204	(	_
92-11	13205-13209	v.20	_
92-12	13210-13211	)	_
92-13	13212-13215	and	_
92-14	13216-13224	GraphPad	_
92-15	13225-13226	(	_
92-16	13227-13232	v.5.0	_
92-17	13233-13234	;	_
92-18	13235-13243	GraphPad	_
92-19	13244-13252	Software	_
92-20	13253-13254	,	_
92-21	13255-13257	La	_
92-22	13258-13263	Jolla	_
92-23	13264-13274	California	_
92-24	13275-13276	)	_
92-25	13277-13278	.	_

93-1	13279-13288	Normality	_
93-2	13289-13291	of	_
93-3	13292-13301	variables	_
93-4	13302-13305	was	_
93-5	13306-13316	determined	_
93-6	13317-13322	using	_
93-7	13323-13326	the	_
93-8	13327-13345	D'Agostino-Pearson	_
93-9	13346-13350	test	_
93-10	13351-13352	.	_

94-1	13353-13356	The	_
94-2	13357-13369	significance	_
94-3	13370-13375	level	_
94-4	13376-13379	for	_
94-5	13380-13383	all	_
94-6	13384-13389	tests	_
94-7	13390-13393	was	_
94-8	13394-13397	set	_
94-9	13398-13400	at	_
94-10	13401-13402	p	_
94-11	13403-13404	<	_
94-12	13405-13408	.05	_
94-13	13409-13410	(	_
94-14	13411-13421	two-tailed	_
94-15	13422-13423	)	_
94-16	13424-13425	.	_

